#price-target

#price-target

Morgan Stanley's revision stems from a broader office sector update tied to job opening data across REIT markets. The underlying concern is structural: white-collar employment trends directly shape office demand, and softening job openings signal a slower leasing recovery than previously modeled.

Citi's concern is mainstream DDR5 16GB DRAM prices have fallen 6% since Micron's earnings report, driven by fears that TurboQuant, an algorithm-based memory compression technology, will structurally reduce memory demand. Citi isn't buying it.

TD Cowen reduced estimates across the household and personal care space, arguing that companies will be unable to fully mitigate higher oil-related input costs stemming from the Iran war.

Guggenheim analyst Seamus Fernandez raised his firm's price target on AstraZeneca to 16,500 GBp from 16,000 GBp, maintaining a Buy rating after updating the firm's model ahead of Q1 earnings.

BTIG rates FTAI a Buy, raising its target from $335 to $340. The firm acknowledges FTAI missed Q4 EBITDA relative to consensus but argues the 2026 setup remains attractive.

The optimism is rooted in Lowe's operational consistency. The company has beaten earnings estimates in all four of its most recent quarters, with the latest Q3 2025 report delivering $3.06 per share versus the $2.81 consensus, an 8.9% surprise. That marks eight consecutive quarterly earnings beats heading into 2026, with an average surprise of 4.1%. Revenue growth of 3.2% year-over-year also outpaces Home Depot's 2.8%.

Stifel has reduced its price target on DoubleVerify to $17 from $20, maintaining a Buy rating but expressing concerns about the overall digital advertising market.